Psg29 Inhibitors
Psg29 inhibitors are a chemical class of compounds designed to inhibit the activity of the Psg29 protein, part of the pregnancy-specific glycoprotein (PSG) family. PSG proteins are a group of carcinoembryonic antigen (CEA)-related cell adhesion molecules known to have diverse functions in various biological processes. The Psg29 protein, like other PSGs, is characterized by its immunoglobulin-like domain structure, making it an important factor in cell-cell adhesion, signaling, and modulation of immune responses. Psg29 inhibitors are small molecules or biologics that specifically bind to the Psg29 protein, hindering its ability to interact with its physiological partners. This inhibition can lead to alterations in signal transduction pathways and downstream cellular effects, depending on the role of Psg29 in different cell types or tissues.
The structural diversity of Psg29 inhibitors is typically influenced by their mode of action, binding specificity, and ability to interfere with the protein's biological functions. These inhibitors may possess functional groups that allow them to establish strong hydrophobic or hydrogen-bonding interactions with the binding pockets of Psg29, effectively blocking its activity. The chemical design of Psg29 inhibitors aims to optimize properties such as binding affinity, selectivity, and stability, ensuring the molecule can effectively engage with Psg29 while minimizing off-target interactions. As a class, Psg29 inhibitors vary in size and structure, ranging from small organic molecules to larger peptides or proteins, with each type offering unique advantages in terms of specificity and potency. Overall, the understanding of Psg29 inhibitors is an ongoing area of biochemical research, with a focus on elucidating their mechanisms of action and improving their molecular interactions with the target protein for enhanced inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin has been shown to inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 by regulating various signaling pathways involved in cell proliferation and differentiation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol has the potential to inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 due to its ability to modulate gene expression and suppress the activity of certain transcription factors involved in the regulation of this protein. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein may inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 through its action on specific receptors and its interference with the signaling pathways responsible for the upregulation of this protein. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin is capable of inhibiting the expression of pregnancy-specific beta-1-glycoprotein 29 by interfering with the activity of certain kinases and transcription factors involved in the regulation of this protein, thus leading to its downregulation. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $90.00 | 1 | |
Berberine may inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 by modulating the expression of key regulatory genes and interfering with specific signaling pathways that are involved in the upregulation of this protein. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate has the potential to inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 through its ability to modulate the activity of certain transcription factors and to interfere with the signaling pathways responsible for the upregulation of this protein. | ||||||
Luteolin | 491-70-3 | sc-203119 sc-203119A sc-203119B sc-203119C sc-203119D | 5 mg 50 mg 500 mg 5 g 500 g | $26.00 $50.00 $99.00 $150.00 $1887.00 | 40 | |
Luteolin may inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 by interfering with the activity of specific kinases and transcription factors involved in the regulation of this protein, thus leading to its downregulation. | ||||||
Fisetin | 528-48-3 | sc-276440 sc-276440A sc-276440B sc-276440C sc-276440D | 50 mg 100 mg 500 mg 1 g 100 g | $51.00 $77.00 $102.00 $153.00 $2856.00 | 7 | |
Fisetin has been shown to inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 by modulating the activity of certain signaling pathways and by interfering with the function of specific regulatory proteins involved in the upregulation of this protein. | ||||||
Baicalein | 491-67-8 | sc-200494 sc-200494A sc-200494B sc-200494C | 10 mg 100 mg 500 mg 1 g | $31.00 $41.00 $159.00 $286.00 | 12 | |
Baicalein is capable of inhibiting the expression of pregnancy-specific beta-1-glycoprotein 29 by modulating the activity of certain kinases and transcription factors involved in the regulation of this protein, thus leading to its downregulation. | ||||||
Silybin | 22888-70-6 | sc-202812 sc-202812A sc-202812B sc-202812C | 1 g 5 g 10 g 50 g | $54.00 $112.00 $202.00 $700.00 | 6 | |
Silibinin may inhibit the expression of pregnancy-specific beta-1-glycoprotein 29 by modulating the expression of key regulatory genes and interfering with specific signaling pathways that are involved in the upregulation of this protein. | ||||||